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Abstract
Recent studies have demonstrated that breast milk contains a population of cells displaying many of the properties typical of 
stem cells. This review outlines progress made in this newly emerging field of stem cell biology and provides an analysis of 
the available data on purification, propagation and differentiation of certain types of progenitor cells from breast milk. The 
possible fates of breast milk cells, including microchimerism caused by their transmission to the distant organs of the infant, 
are also discussed. Unique properties of breast milk-derived stem cells, such as their unusually low tumorigenic potential and 
their negligible ability to form teratomas, are highlighted as obvious advantages for using these cells in regenerative therapy.
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Introduction
Breast-feeding is an indispensable post-parturition stage 
in the process of mammalian reproduction that is crucial 
for neonatal survival during critical periods of their post-
natal development. Each mammalian species has a unique 
composition of milk that has developed during evolution 
to fulfill the requirements of their newborns and infants. In 
humans, the natural reproduction process includes a long 
period when all nutrients and other chemicals required for 
successful physical and intellectual development of a child 
come from milk provided by a lactating mother, emphasizing 
the importance of this biological product. For this reason, 
human breast milk has been intensively studied for many 
years [1, 2].
Not just nutrition supply
It is now well known that in addition to specially balanced 
essential nutrients, breast milk contains functionally distinct 
bioactive components that are involved in remodeling of the 
immune system of neonates and infants, and alter their sus-
ceptibility to different types of infection [3].
Recent studies have revealed the complex supplementa-
tion mechanisms that involve a direct supply of mother’s 
mature immune cells as well as trafficking of other cell 
types supporting the development and functional regulation 
of both the innate and adaptive immune systems of infants 
[4–8]. It has been shown that certain types of cells present 
in breast milk are able to pass through the infant’s gastroin-
testinal tract and populate distant sites such as the spleen, 
liver and lymph nodes [9, 10]. Moreover, communication 
between breast milk components and their natural host, the 
infant, which create a symbiotic commensal relationship, 
have allowed some researchers to suggest that the breast 
milk is a live system and could even be considered an organ 
[11–13].
One of the most remarkable recent findings is the dem-
onstration that infections or other changes in the status 
of the nursed infant trigger a rapid response in secretion, 
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composition and cell contents of consumed breast milk. The 
exact mechanisms of this sophisticated feedback that support 
the dynamic relationship between infant’s homeostasis and 
efficient fulfilling of its immediate needs remain unknown 
[14–16]. The complexity of symbiotic interaction extends 
beyond the eukaryotic cells of mother’s origin and include 
a diverse microbiome that is presumed to colonize the infant 
gastrointestinal tract and, therefore, is a continuous source of 
beneficial bacteria such as Bifidobacterium breve, B. adoles-
centis, B. longum, B. bifidum, B. dentium and others [17–19].
Although study of probiotic bacteria in human milk is 
a very recent and clearly underdeveloped field of research, 
there is already experimental evidence that selected bacte-
ria from the gastrointestinal microbiota of nursing females 
are able to access the mammary gland via the entero-mam-
mary pathway. This transduction occurs by dendritic cells 
and CD18 + cells carrying nonpathogenic bacteria from the 
gut lumen to the lactating mammary gland [20]. It came as 
no surprise that the infant gut becomes actively colonized 
by the breast milk-supplied bacteria, which is ensured by 
the high content and variety of probiotic cells that on aver-
age could comprise  107–108 when around 800 ml of milk 
is consumed daily [12, 21]. This has allowed researchers 
to suggest that human breast milk satisfies the criteria for 
consideration as a probiotic food [22].
Breast milk is also a potential source of some previously 
unrecognized biologically active entities. One recent and 
very exciting finding is the demonstration that the exosomes 
purified from breast milk are able to promote intestinal epi-
thelial cell growth in infants even when they are formula 
feeding [23]. The stimulating effect of breast milk on the 
growth and proliferation of enteroids generated from neona-
tal mice or premature human small intestine have also been 
shown in in vitro experiments [24]. This research further 
substantiates previous suggestions that breast milk could be 
used for therapeutic purposes in combination with conven-
tional drug therapy [2, 25]. Taken together the results of 
these recent studies has substantially broadened our view 
of the function of human breast milk and stimulated further 
research utilizing new approaches and advanced modern 
methods.
Progenitor cells of breast milk
New methods for the identification and separation of cell 
suspensions, such as multicolor flow cytometry, allow for the 
accurate assessment and quantification of the cell composi-
tion of biological fluids. Implementation of these methods 
has already significantly advanced our current knowledge 
about various cell populations present in breast milk. Cells 
of eukaryotic origin (i.e., excluding probiotic bacteria) 
found in breast milk can be pooled in to two major groups: 
blood-derived and breast-derived cells, and in both these 
pools small groups of progenitor or stem cells have been 
identified [26–29].
Not surprisingly, the largest proportion of total cell counts 
in breast milk is  CK18+ luminal epithelial cells and beta-
casein-positive lactocytes that synthesize milk proteins. In 
human milk produced by healthy nursing females feeding 
healthy infants luminal and myoepithelial cells together 
could constitute up to 98% of all cells [30]. However, the 
epithelial component of breast milk includes not only mature 
epithelial cells, but also their precursors and stem cells [30]. 
One of the most important and still not fully addressed ques-
tions is the identity of the source and origin of multipotent 
cells found in breast milk. The mammary gland employs 
a sophisticated machinery for converting the resting non-
lactating mammary gland into a milk-secretory organ, which 
requires substantial expansion and cellular differentiation 
from the original source of progenitor cells [31–34]. Nor-
mally these stem cells remain in quiescent niches before they 
start asymmetric division and undergo their ductal-alveolar 
morphogenesis during pregnancy and lactation. Activation 
of certain intracellular pathways, for example the Wnt-sign-
aling pathway, that is associated with continued morphogen-
esis, supports the high rate of surviving and expansion of 
these cells in culture [35].
The committed stem cell progeny are seen as an impor-
tant source of human stem cells for therapeutic purposes 
[36–38]. These cells could also be advantageous for cancer 
research, particularly for revealing the role of proliferation-
responsive cell populations in tumorigenesis, when they 
escape the control mechanisms that hold them in quiescence 
in the resting mammary gland [39, 40]. Cregan et al. have 
studied cultured cells from breast milk and provided the first 
evidence that some of these cells exhibit the properties of 
stem cells [26]. A substantial proportion of cells in cultures 
established from donor milk were positively stained for 
cytokeratin 5  (CK5+), a mammary stem cell marker. In the 
lactating mammary gland,  CK5+ cells usually present in the 
alveoli and ducts of the epithelium and most probably they 
represent the source of  CK5+ cells in cultures obtained from 
donor milk. However, the source of these cells and their pos-
sible role in milk is still enigmatic [41].
Other cells with characteristics typical for stem cells were 
also found in cultures established from cells present in breast 
milk. These include cells expressing α6 integrin (CD49f), 
a mammary stem cell marker, and an epithelial progenitor 
marker p63 [28, 42, 43]. Systematic in vitro research pro-
vided by Thomas et al. confirmed that a subpopulation of 
cells cultured from breast milk not only express stem cell 
markers but also exhibit the major features of multipotency. 
These cells are capable of renewing themselves, and under 
certain conditions are able to undergo differentiation towards 
at least two types of epithelial lineages that give origin to 
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either milk proteins-producing  CK18+ luminal cells, or 
 CK14+ myoepithelial cells [28, 42].
These groundbreaking reports have boosted further 
research on the cellular components of breast milk. Remark-
ably, all the main findings reported in the original publica-
tions have been successfully confirmed using colony-form-
ing assays carried out by other laboratories and our own 
unpublished data [12, 27]. Moreover, in culture, a subpopu-
lation of breast milk-derived stem cells display very high 
multilineage potential, resembling those typical for human 
embryonic stem cells, hESCs [29]. This subpopulation has 
been designated as “hBSCs” (for human breast milk stem 
cells), however, it would probably be more appropriate to 
use the abbreviation “hBmSCs” to avoid potential confusion 
with the breast stem cells originated from tissue biopsy of 
the mammary gland.
So far, no differentiation techniques specific for cultivated 
milk cells into various cell lineages have been developed but 
methods and factors commonly used for differentiation of 
progenitor cells of other origin linage have been successfully 
employed. Sani et al. [44] cultivated purified human breast 
milk-derived stem cells and achieved their differentiation 
toward different lineages, again suggesting the presence of 
a pool of pluripotent cells in these cultures. A large pro-
portion of these cells expressed the mesenchymal stem cell 
markers: CD44, CD90, CD271, and CD146. A smaller sub-
population of these hBmSCs also expressed the embryonic 
stem cell markers: Oct4, Sox2, TRA 60-1, Nanog but not 
SSEA1 or SSEA 4. Another population comprised of cells 
that expressed cytokeratin 18, a marker for luminal mam-
mary epithelial cells, were capable of differentiating into 
adipocytes and osteoblasts. Moreover, under certain condi-
tions formation of neurospheres that were stained positively 
for nestin and some neuron and glial-specific markers were 
also observed [44, 45].
In another study, the hBmSCs were found positively 
labeled with the stage-specific embryonic antigen 4 marker 
(SSEA4) as well as TRA-1-60 and TRA-1-81 antigens, both 
markers for undifferentiated pluripotent human stem cells. 
Furthermore, the ability of cultured hBmSCs to differen-
tiate under certain conditions towards different epithelial 
lineages (including myoepithelial cells and lactocytes), and 
to form mini-mammary glands secreting milk proteins has 
been demonstrated [13]. Perhaps more importantly, hBm-
SCs appeared to be truly multipotent, since they were able 
to undergo the mesodermal route and differentiate into 
osteoblasts-like cells, chondrocytes, adipocytes and cardio-
myocytes, and were also able to differentiate into cells of 
endodermal origin, such as pancreatic beta-like cells pro-
ducing insulin and hepatocyte-like cells producing albumin. 
Finally, hBmSCs were additionally shown to differentiate 
into various cells of ectodermal origin including glia-like 
and neuron-like cells that express neuronal-specific markers 
such as βIII-tubulin [27, 29, 46]. Further analysis of expres-
sion patterns for genes, that are commonly used as markers 
of pluripotency, confirmed their activation in hBmSCs [47]. 
The levels of OCT4 (POU class 5 homeobox1), SOX2 (sex 
determining region Y-box 2), NANOG (nanog homeobox) 
and KLF4 (Kruppel-like factor 4) mRNAs were significantly 
increased. Immunohistochemical staining has confirmed the 
presence of the encoded proteins. Interestingly, the levels of 
expression of these genes in the fraction of freshly isolated 
cells from the milk samples varied between 17 donors with 
the highest level detected for an individual who was concur-
rently breastfeeding and pregnant. This is consistent with the 
expansion of mammary gland tissue and consequent increase 
of the mammary stem cell niche during pregnancy [13, 29].
The presence of a novel stem cell population with mul-
tilineage differentiation potential has also been recently 
identified in bovine milk. This cells isolated and character-
ized by Pipino et al. were able to grow as a plastic-adherent 
culture and differentiate into osteogenic, chondrogenic, 
and adipogenic lineages [48]. This heterogeneous popula-
tion of epithelial-like and spindle-shaped bovine milk stem 
cells (bMSCs) was positive for the typical epithelial mark-
ers E-cadherin, cytokeratin-14, cytokeratin-18, and smooth 
muscle actin, but a subset of purified milk cells (30–40%) 
displayed typical mesenchymal surface antigens CD90, 
CD73, and CD105. Furthermore, a similar percentage of 
bMSCs expressing CD90, CD73, and CD105 presented the 
stemness markers SOX2 and OCT4 in their nuclei.
In a recent study of cell populations that exhibit a stem 
cell phenotype, Briere et al. compared breast milk samples 
obtained from feeding mothers of preterm infants and full-
term infants and found obvious differences in the proportion 
of stem-like cells in these two types of samples. Further 
confirmation of this observation has been demonstrated by 
showing distinct patterns of expression of stem cell-specific 
genetic markers in theses two samples [49]. The latter results 
are linked to an intriguing but completely unresolved ques-
tion about a potential symbiotic relationship between a feed-
ing mother and nursing infant: if and how this relationship 
underlines the complement and phenotype of hBmSCs. 
There is some experimental evidence that the cross-talk 
between the infant and the consumption of milk regulates 
the gene expression in breast-milk cells [50, 51].
Due to the physico-chemical properties of breast milk, 
purification of its cellular components with a quality 
sufficient for the immediate analysis by flow cytometry 
methods that would be sensitive enough to detect the pool 
of cells displaying pluripotency markers is a challeng-
ing task. The main problem is the ability to discriminate 
between cells and noncellular components. Keller et al. 
have developed an improved protocol that use a recently 
developed staining agents DRAQ5™ far red and  SYTOX® 
blue for flow cytometry analysis of breast cells in human 
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milk. This novel and reliable approach allowed to iden-
tify and quantify subpopulation of  CD11b+ monocytes as 
well as putative stem cells positive for cell surface markers 
TRA-1-81 and SSEA-4 [52]. Interestingly, for TRA-1-81+ 
putative stem cells the high variations were detected in 
samples without significant differences between the ges-
tational age groups.
Taken together, the available experimental evidence 
suggests that hBmSCs are able to differentiate into all 
three germ layers (Fig. 1) and that the level of their pluri-
potency is comparable with that of human embryonic stem 
cells. However, the amount of stem cells in the milk, their 
phenotype, and expression of cell markers of pluripotency 
could vary between milk donors [53] (Fig. 2).
So far, no published data provide strong enough experi-
mental evidence for the origin of hBmSCs. Nevertheless, 
Hassiotou and Hartmann have recently suggested that at 
least some subpopulations of hBmSCs could have the same 
origin as hematopoietic stem cells [13]. The presence of 
other blood-derived cells in breast milk indirectly supports 
this notion. For example, the presence of  CD34+ hemat-
opoietic stem/progenitor cells has been demonstrated in 
colostrum and breast milk and it is highly probable that 
they originate from the maternal bloodstream [41, 54]. 
However, the exact mechanisms of their delivery into 
breast milk as well as the physiological roles of hemat-
opoietic stem/progenitor cells in early postnatal develop-
ment in infants remain unclear.
Microchimerism caused by transmission 
of breast milk cells
Transmission of cells from mother to fetus and from fetus 
to mother via the placenta, and from feeding mothers 
to nursing infants via breast milk has been studied for 
several decades and is well documented [9, 10, 55–60]. 
Therefore, there is little doubt about the existence of effi-
cient mechanisms of seeding infants with maternal cells, 
although their functional consequences and importance 
for the recipient remain elusive. There is some experi-
mental evidence that hBmSCs can cross the wall of the 
gastrointestinal tract of nursed mouse pups, enter their 
circulatory system and reach different organs where they 
differentiate and become fully functional [61]. This phe-
nomenon creates a type of microchimerism similar to that 
described as a result of stem cell exchange between the 
mother and the fetus in utero. In the latter case, seeded 
cells were able to survive in the chimeras for several years 
[55, 62–64] and it is feasible that cells which originated 
from breast milk might follow the same fate. Studies on 
breastfed rabbits have demonstrated that purified milk-
derived stem cells labeled with PKH26 Red Fluorescent 
Cell Linker were engrafted into the offspring organs and 
were detected in liver, cartilage, bone and duodenum 
[65]. In the very recent research by Aydın et al., lactat-
ing transgenic female mice expressing green fluorescent 
Fig. 1  Composition of breast 
milk cellular component and 
markers of pluripotency identi-
fied in a fraction of presumptive 
breast milk stem cells. Available 
experimental evidence suggest 
that there is a small fraction of 
cells (BmSCs) displaying key 
properties of stem cells in breast 
milk amongst various types 
of other cells that are present. 
BmSCs are able to differenti-
ate into cells of all three germ 
layers and the level of their 
pluripotency is comparable with 
that of human embryonic stem 
cells
Stem cells in human breast milk 
1 3
protein  (GFP+) were used for fostering and breastfeed-
ing wild-type newborn pups. The maternal  GFP+ cells 
in the suckling’s blood and in the brain have been identi-
fied by fluorescence-activated cell sorting, polymerase 
chain reaction and immunohistochemistry. Moreover, the 
authors have provided experimental evidence that  GFP+ 
cells have differentiated into both neuronal and glial cell 
types in the brain after being foster fed by  GFP+ female 
mice. These data strongly suggest that  GFP+ cells were 
delivered to offspring by breast milk and were able to 
differentiate into different types of cells [66].
Research on microchimerism generated by consumed 
breast milk cells has firmly supported the important phys-
iological role of this process in the efficient maturation 
of the infant immune system [67, 68]. For example, one 
possible consequence of microchimerism is an increased 
tolerance of the recipient to donor antigens and this evi-
dence is indirectly supported by the improved accept-
ance of maternal transplants by individuals who were 
breastfed as infants [69, 70]. Other effects of breast milk 
cell-induced microchimerism cannot be excluded and, 
therefore, further studies are required to understand its 
mechanisms and physiological role.
Potential therapeutic use of breast 
milk‑derived cells
The discovery of hBmSCs and identification of cells dif-
ferentiated from hBmSCs in various organs of recipients 
paved the way to the idea that breast milk is a novel prom-
ising source of transplantable stem cells for therapeutic 
use. An important reason why hBmSCs are included in 
the list of prospective sources of human pluripotent cells 
for use in regenerative medicine is their unusually low 
tumorigenic potential and the negligible ability to form 
teratomas [29]. Another major advantage of hBmSCs is 
relatively easy access and straightforward harvesting that 
does not involve any invasive techniques. Therefore, for 
some patients they represent a promising source of cells 
for autologous transplantation, particularly if further pro-
gress in regulated induction of milk production by dor-
mant breast tissue and detailed characterisation of the cell 
composition of induced milk is achieved [71].
So far, stroke therapy seems to be the most attractive 
application for hBmSC transplantation. In a comprehen-
sive report that compared various stem cell types for their 
Fig. 2  Dissemination of breast milk cells throughout the body of nursed infants. A fraction of breast milk progenitor cells is able to penetrate the 
wall of the gastrointestinal tract of nursed infants, entering their circulatory system and populating distant organs
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potential efficacy to sequester stroke-induced neuroinflam-
mation, feasibility as translational clinical cell sources, 
safety and suitability as a transplantable material, hBmSCs 
have been suggested as a promising source of stem cells 
for treatment of a stroke-associated pathology [72]. This 
concept for the potential therapeutic benefit of hBmSCs 
is largely based on results of in vitro studies where hBm-
SCs were cultured and differentiated in vitro followed by 
identification of the growth factors that they secreted [73, 
74]. Of particular importance for stroke therapy is the abil-
ity of certain subpopulations of these differentiated cells 
to produce VEGF and HGF and a protocol for culturing 
breast milk-derived cells that increase production of these 
factors has been established [73].
Other recently developed protocols allow in vitro dif-
ferentiation of hBmSCs into various types of neuronal and 
glial cells, including pentraxin3 producing astrocytes [29, 
75]. Since pentraxin 3 can promote blood brain barrier 
(BBB) integrity, these hBmSC-derived astrocytes may 
have the capacity to encourage suppression of peripheral 
immune invasion after ischemic stroke. Another poten-
tially beneficial effect of transplanted hBmSCs on BBB 
is due to their ability to differentiate into endothelial-like 
cells that could regulate the immune microenvironment in 
the brain regions affected by stroke and might contribute 
to local restoration of the BBB [72].
The current major limitation for clinical applicabil-
ity of breast-milk-derived stem cells for treating stroke 
is the lack of knowledge about their therapeutic poten-
tial in vivo, particularly about their restorative effects, 
efficacy and safety [76]. For the comprehensive use of 
breast milk-derived cells in regenerative therapy, there 
is an immediate need for characterizing properties of the 
milk cellular component after induced lactation. There is 
currently no data on the cell composition and pluripotent 
characteristics of induced breast milk, in which, produc-
tion has not been the consequence of child birth but caused 
by hormonal stimulation, for example in case of adoptive 
female mother or transgendered male-genotype mother, 
although the methods of induced lactation are well estab-
lished [77–79]. Therefore, studies in animal models are 
still required before hBmSCs can be firmly considered 
for therapeutic intervention for stroke and potentially, 
other human diseases. These studies should be focused 
on revealing and characterizing the pattern of cell com-
position and the potential teratogenic properties of cells 
present in induced breast milk. Another important line of 
future research is the development of new methods for fine 
tuning the stem cell composition of induced donor milk.
In conclusion, there are more questions than answers in 
the story of breast milk stem cells but this field is rapidly 
gaining momentum and might bring surprising results and 
unexpected benefits.
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